NCT02970318 2026-02-06A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLAcerta Pharma BVPhase 3 Active not recruiting310 enrolled 18 charts 1 FDA
NCT02475681 2025-08-27ElevateTNAcerta Pharma BVPhase 3 Active not recruiting535 enrolled 19 charts 1 FDA